Centrexion Therapeutics

Centrexion Therapeutics is a clinical-stage biotech targeting two high-value, high-unmet-need sectors: non-opioid chronic pain and immunology. The company leverages deep expertise in pain pathophysiology and autoimmune drug development to build a diversified pipeline of novel candidates. With a seasoned leadership team and strategic partnerships with entities like Eli Lilly and Boehringer Ingelheim, Centrexion is positioned to capitalize on growing governmental and private support for non-opioid analgesics and next-generation immunology medicines.

Target-agnostic drug development based on deep understanding of pain pathophysiology and immunology, focusing on novel, specific mechanisms for chronic pain and differentiated targets in inflammation.

The non-opioid pain market is highly competitive, with numerous companies exploring novel mechanisms (e.g., NaV1.7/1.8 inhibitors, NGF antibodies, TRP channel modulators). The immunology space is dominated by biologic therapies and a rapidly evolving landscape of targeted small molecules and biologics, requiring highly differentiated products to succeed.